Why the study?
Outpatient worsening heart failure is adversely prognostic in heart failure, but its prognostic value and the effect of patisiran in transthyretin amyloidosis with cardiomyopathy remained to be investigated.
Does patisiran reduce outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy?
Does patisiran reduce outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy?
In patients with transthyretin amyloidosis with cardiomyopathy, outpatient worsening heart failure is frequent, strongly prognostic for mortality and cardiovascular events, and its risk is significantly reduced by patisiran.
Answers are grounded in this paper and cite their sources.
Outpatient worsening HF marks higher mortality risk in ATTR-CM; supports patisiran evaluation in randomized trials.
BACKGROUND: Outpatient worsening heart failure (HF), defined by initiation or intensification of diuretics, is adversely prognostic for patients with either reduced or preserved ejection fraction. OBJECTIVES: This study sought to investigate the prognostic value of outpatient worsening HF in transthyretin amyloidosis with cardiomyopathy and the effect of patisiran treatment. METHODS: Post hoc analyses of the APOLLO-B trial (NCT03997383) evaluated the associations between outpatient worsening HF (defined by oral diuretic initiation or intensification), measures of disease progression, and a composite endpoint of all-cause mortality and cardiovascular (CV) events. We further examined the effect of patisiran on outpatient worsening HF over 24 months (ie, during the double-blind and open-label extension periods). RESULTS: In APOLLO-B, 144 (40.1%) patients had no event, 157 (43.7%) had outpatient worsening HF, 13 (3.6%) required an urgent HF visit, 118 (32.9%) had a CV hospitalization, and 47 (13.1%) died. Outpatient worsening HF was associated with an increased risk of all-cause mortality and CV events (HR: 2.21; 95% CI: 1.58-3.08), as well as a greater deterioration in 6-minute walk test distance, Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and NYHA functional class and a greater increase in N-terminal prohormone of B-type natriuretic peptide. Addition of outpatient diuretic initiation or intensification to the composite endpoint of all-cause mortality and CV events increased the overall number of patients having an event from 141 to 215 (a 52% increase). Patisiran reduced the risk of outpatient worsening HF (HR: 0.70; 95% CI: 0.51-0.96) over 24 months. CONCLUSIONS: During APOLLO-B, outpatient worsening HF in patients with transthyretin amyloidosis with cardiomyopathy was frequent, prognostic, and reduced by patisiran.
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: